Jill E Slansky
Overview
Explore the profile of Jill E Slansky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1502
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jordan K, Sikora M, Slansky J, Minic A, Richer J, Moroney M, et al.
Clin Cancer Res
. 2020 Sep;
26(23):6362-6373.
PMID: 32928797
Purpose: Ovarian cancer has one of the highest deaths to incidence ratios across all cancers. Initial chemotherapy is effective, but most patients develop chemoresistant disease. Mechanisms driving clinical chemo-response or...
12.
Katz S, Moody A, Guha P, Hardaway J, Prince E, LaPorte J, et al.
J Immunother Cancer
. 2020 Aug;
8(2).
PMID: 32843493
In recent years, cell therapy technologies have resulted in impressive results in hematologic malignancies. Treatment of solid tumors with chimeric antigen receptor T-cells (CAR-T) has been less successful. Solid tumors...
13.
Hoffmann M, Slansky J
Mol Carcinog
. 2020 May;
59(7):862-870.
PMID: 32386086
The strength of the interaction between T-cell receptors (TCRs) and their ligands, peptide/major histocompatibility complex complexes (pMHCs), is one of the most frequently discussed and investigated features of T cells...
14.
Fajrial A, He Q, Wirusanti N, Slansky J, Ding X
Theranostics
. 2020 May;
10(12):5532-5549.
PMID: 32373229
Gene editing is a versatile technique in biomedicine that promotes fundamental research as well as clinical therapy. The development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) as a genome...
15.
Slansky J, Nakayama M
Semin Immunol
. 2020 Mar;
47:101395.
PMID: 32205022
T cells recognize and respond to self antigens in both cancer and autoimmunity. One strategy to influence this response is to incorporate amino acid substitutions into these T cell-specific epitopes....
16.
Westrich J, Vermeer D, Silva A, Bonney S, Berger J, Cicchini L, et al.
Oncogene
. 2019 Aug;
38(46):7166-7180.
PMID: 31417179
Evasion of the host immune responses is critical for both persistent human papillomavirus (HPV) infection and associated cancer progression. We have previously shown that expression of the homeostatic chemokine CXCL14...
17.
Rabe J, Gardner L, Hunter R, Fonseca J, Dougan J, Gearheart C, et al.
Cancer Res
. 2019 May;
79(14):3702-3713.
PMID: 31142509
Exploitation of the immune system has emerged as an important therapeutic strategy for acute lymphoblastic leukemia (ALL). However, the mechanisms of immune evasion during leukemia progression remain poorly understood. We...
18.
Slansky J, Spellman P
N Engl J Med
. 2019 Feb;
380(9):877-880.
PMID: 30811916
No abstract available.
19.
Greene L, Bruno T, Christenson J, DAlessandro A, Culp-Hill R, Torkko K, et al.
Mol Cancer Res
. 2018 Aug;
17(1):131-139.
PMID: 30143553
Tryptophan catabolism is an attractive target for reducing tumor progression and improving antitumor immunity in multiple cancers. Tumor infiltration by CD8 T cells correlates with improved prognosis in triple-negative breast...
20.
Vartuli R, Zhou H, Zhang L, Powers R, Klarquist J, Rudra P, et al.
J Clin Invest
. 2018 May;
128(6):2535-2550.
PMID: 29757193
Eya proteins are critical developmental regulators that are highly expressed in embryogenesis but downregulated after development. Amplification and/or re-expression of Eyas occurs in many tumor types. In breast cancer, Eyas...